| Document |
Document Title |
|
JP5295148B2 |
To provide a method for holding gaseous molecules in a line, to provide a material holding the gaseous molecules in such the way, to provide a method for producing the material, and to provide a high-performance sensor. The porous coordi...
|
|
JP5248783B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP5246448B2 |
Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted ...
|
|
JP5218788B2 |
A retroviral protease inhibiting compound of formula (A) is disclosed for use in combination with other active pharmaceutical agents for treating a human infected by HIV. Intermediates and processes useful in the manufacture of compounds...
|
|
JP5205258B2 |
There is provided a class of crosslinking compound, said compound comprising (i) one or more fluorinated aromatic group; and (ii) one or more ionizable group, wherein the crosslinking compound is soluble in at least one polar solvent. Me...
|
|
JP2013508355A |
Disclosed are a novel, simple and low-cost method for preparing sitagliptin of formula (I), as DPP-IV (dipeptidyl peptidase IV) inhibitor, which is useful in treating type 2 diabetes mellitus and key intermediates used in said preparatio...
|
|
JP5130417B2 |
The present invention provides novel 4-dedimethylaminotetracycline compounds that are substituted at the 9 position and the use of said compounds for the manufacture of a medicament for the treatment of a mammal suffering from a conditio...
|
|
JP5118502B2 |
Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydro...
|
|
JP5113979B2 |
This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpecte...
|
|
JP5110424B2 |
|
|
JP5060685B2 |
The present invention provides novel 4-dedimethylaminotetracycline compounds that are substituted at the 9 position and the use of said compounds for the manufacture of a medicament for the treatment of a mammal suffering from a conditio...
|
|
JP5025652B2 |
An amide is formed by reacting an α-ketoacid or salt thereof in a decarboxylative condensation reaction with an amine or salt thereof comprising a nitrogen covalently bound to an atom selected from oxygen, nitrogen, and sulfur. The amid...
|
|
JP5004075B2 |
To provide a new cyclic ether amide lipid constructing molecular aggregates by self-organization, and a lipid membrane forming a moderate intramolecular hydrogen bond. This new cyclic ether amide lipid of 2 glycerol derivatives and 2 lon...
|
|
JP4963771B2 |
7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.
|
|
JP4944344B2 |
The invention relates to a novel process for the preparation of certain cyclopropyl carboxylic acid esters and other cyclopropyl carboxylic acid derivatives; to the use of certain cyclopropyl carboxylic acid esters in a process for the p...
|
|
JP4939216B2 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
JP2012082155A |
To provide a triazolium salt and a method for producing the same, a method for producing an alkylated oxindol having tetrasubstituted carbon by using an azide alcohol, and a triazolium salt as a catalyst, in an asymmetric reaction.The tr...
|
|
JP4922521B2 |
From compounds of formula II wherein R1 and R2 are independently of one another H, C1-C6alkyl, C1-C6halogenalkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, or C1-C6alkoxy-C1-C6alkyloxy, R3 is C1-C6alkyl, R4 is C1-C6alkyl, and R5 is C1-C6alkyl...
|
|
JP2012056895A |
To provide a novel compound to quickly modify RNA in a specific sequence and in a specific site.The compound is shown by general formula II. In the formula, R1 is H, C1-6 alkyl or C1-6 aryl; and X is Br, Cl or I. The compound shown by th...
|
|
JP4900755B2 |
Compounds of formula (II) are simultaneously halogenated in the 5 position and hydroxylated in the 4 position under lactonization, the halolactone is converted into a hydroxylactone and then the hydroxy group into a leaving group, the le...
|
|
JP4902361B2 |
Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compound...
|
|
JP2012006921A |
To provide a new high-yield and practical chemical synthetic method of oseltamivir phosphate, with which the oseltamivir phosphate is obtained from an easily available raw material compound with high optical purity.In the new chemical sy...
|
|
JP4853888B2 |
Compounds of formula (XII), are simultaneously halogenated in the 5 position and hydroxylated in the 4 position under lactonization, the halolactone is reacted with an amine to form a carboxamide, the halogen is replaced with azide, if n...
|
|
JP4851020B2 |
The invention provides a multistep synthesis for the preparation of 4,5-diamino shikimic acid derivatives of formula starting from an isophtalic acid derivative of formula 4,5-Diamino shikimic acid derivatives are potent inhibitors of vi...
|
|
JP2011236229A |
To provide use of certain cyclopropyl carboxylic acid esters in a process for the preparation of intermediates that can be used in the synthesis of pharmaceutically active entities, and to provide the intermediates provided by these proc...
|
|
JP4815566B2 |
The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides phar...
|
|
JP4787160B2 |
The present invention is directed a method of flame retarding a polymeric substrate using a specific group of azo and peroxide derivatives as flame retardants, to flame retardant compositions as well as to novel azo compounds usable as f...
|
|
JP4779058B2 |
The present invention relates to filed of pharmaceutical chemistry. Disclosed are a series of ±-amino-N-substituted amide compounds having a structure of the following formula, the pharmaceutically acceptable salts thereof, and the phar...
|
|
JP4768638B2 |
The present invention relates a process for stereoselective or regioselective chemical synthesis which generally comprises reacting a nucleophile and a chiral or prochiral cyclic substrate in the presence of a non-racemic chiral catalyst...
|
|
JP4748338B2 |
The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibit...
|
|
JP4742220B2 |
Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted ...
|
|
JP2011140488A |
To provide a peptidomimetic compound which inhibits the NS3 protease of a flavivirus of hepatitis C virus (HCV).The compound is represented by formula (VI).
|
|
JP4711275B2 |
|
|
JP4663193B2 |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders are disclosed.
|
|
JP2011052014A |
To provide an effective ocular hypotensive agent and a widely applicable smooth muscle relaxant.A cyclopentaneheptanoic acid, 2-cycloalkyl or arylalkyl derivative substituted with halo, methyl, hydroxy, nitro, amino, amide, azide, oxime,...
|
|
JP2011503226A |
The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C 1 -C 8 )-alkyl; followe...
|
|
JP4580606B2 |
From compounds of formula II wherein R1 and R2 are independently of one another H, C1-C6alkyl, C1-C6halogenalkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, or C1-C6alkoxy-C1-C6alkyloxy, R3 is C1-C6alkyl, R4 is C1-C6alkyl, and R5 is C1-C6alkyl...
|
|
JP2010180245A |
To provide binding methods and use methods of androgen receptor targeting agents (ARTA).The agents define a new subclass of selective androgen receptor modulators (SARM) compounds. Several SARM compounds are found to have an unexpected a...
|
|
JP4500304B2 |
A method of forming a polymer device including the steps (i) of depositing on a substrate a solution containing a polymer or oligomer and a crosslinking moiety, to form a layer, and, (ii) curing the layer formed in step (i) under conditi...
|
|
JP2010521446A |
The invention provides a composition comprising ( S ) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-e
thanol, wherein the composition is either substantially free of ( R ) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-p...
|
|
JP2010519182A |
The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have reduced immunogenicity as well as longer life time in v...
|
|
JP2010043102A |
To provide new chemically modified 4-dedimethylaminotetracycline compounds.The 4-dedimethylaminotetracycline compounds have structure P (wherein, R8 is hydrogen; and R9 is nitro), and are 9-amino-4-dedimethylamino-6-deoxytetracycline, 4-...
|
|
JP2010045051A |
To provide a method and material for patterning of a polymerizable, amorphous matrix with electrically active material such as a light emitting material disposed therein; and to provide an element formed using the same.In a method of mak...
|
|
JP4422895B2 |
Novel compounds of Formula (I) are described. R1, R2, R3, R4, R5 and R6 are described in this specification. Synthetic intermediates and pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods o...
|
|
JP4421141B2 |
|
|
JP2010037332A |
To provide a new chiral iridium aqua complex which has good storage stability, can be easily produced, and can achieve a high yield and high stereoselectivity in an asymmetric transfer hydrogenation reaction.The chiral iridium aqua compl...
|
|
JP4347906B2 |
PCT No. PCT/GB96/01208 Sec. 371 Date Nov. 21, 1997 Sec. 102(e) Date Nov. 21, 1997 PCT Filed May 20, 1996 PCT Pub. No. WO96/37628 PCT Pub. Date Nov. 28, 1996A process for preparing a compound of Formula (3) in which R2 is -H; which compri...
|
|
JP4347488B2 |
A process for the addition of an azide function to an organic compound in which process a mixture is prepared by adding an epoxide-derivative of the organic compound and an alkali metal azide salt to a solvent is described. The mixture i...
|
|
JP4343398B2 |
|
|
JP2009167210A |
To provide a new synthetic method and a composition and to provide a new method for preparing an intermediate useful in the synthesis of neuraminidase inhibitor and to provide a composition useful as an intermediate that is itself useful...
|
